Innovent Biologics, Inc. develops, manufactures and commercializes biopharmaceutical medicines for oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas. News from Innovent centers on product approvals and commercial updates in China, clinical and preclinical data for pipeline assets, medical-congress presentations, and partner-reported development updates. Recurring drug and program references include mazdutide for type 2 diabetes, IBI363 in cancer immunotherapy, IBI324/OLN324 for retinal disease, tigulixostat/IBI128 for gout, and immunology assets such as picankibart/IBI112, IBI3013 and IAR129.
Innovent Biologics (IVBIY) presented Phase 3 clinical study results (DREAMS-1) for mazdutide, their dual GCG/GLP-1 receptor agonist, at the ADA 85th Scientific Sessions. The study, involving 319 Chinese patients with type 2 diabetes, demonstrated significant efficacy with HbA1c reduction of 2.15% and body weight reduction of up to 7.81% after 24 weeks of treatment.
The trial met its primary and secondary endpoints, showing superior results compared to placebo. 87.4% of participants receiving mazdutide 6 mg achieved HbA1c <7.0%. The drug also showed improvements in cardiometabolic risk factors with a favorable safety profile. Two NDAs for mazdutide are currently under review by China's NMPA for chronic weight management and glycemic control.